Trial Profile
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2015
Price :
$35
*
At a glance
- Drugs Mapracorat (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Bayer
- 23 Dec 2014 New trial record